Gilead's new drug keeps 56 pct of lymphoma trial patients alive
December 10, 2017 at 10:30 AM EST
Dec 10 (Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday.
